pI: 8.1452 |
Length (AA): 378 |
MW (Da): 42922 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 7 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
1 | 165 | 2g2k (A) | 1 | 156 | 40.00 | 0 | 0.99 | 0.63 | 1.18 |
10 | 139 | 2d74 (B) | 20 | 138 | 27.00 | 0 | 0.99 | 0.62 | -0.08 |
230 | 370 | 2iu1 (A) | 243 | 382 | 16.00 | 0 | 0.64 | 0.69 | -1.4 |
2 | 155 | 2e9h (A) | 5 | 156 | 41.00 | 0 | 1 | 0.898507 | -0.3 |
10 | 140 | 2d74 (B) | 20 | 139 | 26.00 | 0 | 1 | 0.621661 | -0.14 |
219 | 375 | 3jui (A) | 545 | 715 | 10.00 | 0.0000000011 | 0.14 | 0.477444 | -0.97 |
219 | 309 | 1dlc (A) | 158 | 245 | 28.00 | 0.092 | 0.9 | 0.548241 | -0.46 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | amastigotes, metacyclic. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_127779)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G36730 | probable eukaryotic translation initiation factor 5-1 |
Arabidopsis thaliana | AT1G77840 | putative eukaryotic translation initiation factor 5-2 |
Babesia bovis | BBOV_III001090 | eukaryotic translation initiation factor 5, putative |
Brugia malayi | Bm1_56790 | eukaryotic translation initiation factor 5 |
Candida albicans | CaO19.11737 | similar to S. cerevisiae TIF5 (YPR041W) translation initiation factor eIF5 |
Candida albicans | CaO19.4261 | similar to S. cerevisiae TIF5 (YPR041W) translation initiation factor eIF5 |
Caenorhabditis elegans | CELE_C37C3.2 | Protein C37C3.2, isoform A |
Cryptosporidium hominis | Chro.70278 | hypothetical protein |
Cryptosporidium parvum | cgd7_2430 | translation initiation factor eIF-5; Tif5p, ZnR+W2 domains |
Dictyostelium discoideum | DDB_G0286753 | eukaryotic translation initiation factor 5 |
Drosophila melanogaster | Dmel_CG9177 | CG9177 gene product from transcript CG9177-RD |
Echinococcus granulosus | EgrG_001188400 | Eukaryotic translation initiation factor 5 |
Entamoeba histolytica | EHI_129770 | Eukaryotic translation initiation factor eIF-5 |
Echinococcus multilocularis | EmuJ_001188400 | Eukaryotic translation initiation factor 5 |
Giardia lamblia | GL50803_15538 | Eukaryotic translation initiation factor 5 |
Homo sapiens | ENSG00000100664 | eukaryotic translation initiation factor 5 |
Leishmania braziliensis | LbrM.20.0320 | eukaryotic translation initiation factor 5, putative |
Leishmania donovani | LdBPK_340370.1 | eukaryotic translation initiation factor 5, putative |
Leishmania infantum | LinJ.34.0370 | eukaryotic translation initiation factor 5, putative |
Leishmania major | LmjF.34.0350 | eukaryotic translation initiation factor 5, putative |
Leishmania mexicana | LmxM.33.0350 | eukaryotic translation initiation factor 5, putative |
Loa Loa (eye worm) | LOAG_00592 | hypothetical protein |
Loa Loa (eye worm) | LOAG_00591 | eukaryotic translation initiation factor 5 |
Mus musculus | 102641436 | eukaryotic translation initiation factor 5-like |
Mus musculus | ENSMUSG00000021282 | eukaryotic translation initiation factor 5 |
Neospora caninum | NCLIV_019200 | Eukaryotic translation initiation factor 5, related |
Oryza sativa | 4346742 | Os09g0326900 |
Oryza sativa | 9272123 | Os06g0698674 |
Onchocerca volvulus | OVOC6371 | Eukaryotic translation initiation factor 5 homolog |
Plasmodium berghei | PBANKA_0605300 | eukaryotic translation initiation factor 5, putative |
Plasmodium falciparum | PF3D7_1206700 | eukaryotic translation initiation factor 5, putative |
Plasmodium knowlesi | PKNH_1306700 | eukaryotic translation initiation factor 5, putative |
Plasmodium vivax | PVX_084370 | eukaryotic translation initiation factor 5, putative |
Plasmodium yoelii | PY07150 | hypothetical protein |
Saccharomyces cerevisiae | YPR041W | translation initiation factor eIF5 |
Schmidtea mediterranea | mk4.003959.00 | Eukaryotic translation initiation factor 5 |
Schmidtea mediterranea | mk4.018235.00 | Eukaryotic translation initiation factor 5 |
Schmidtea mediterranea | mk4.000325.14 | Eukaryotic translation initiation factor 5 |
Schmidtea mediterranea | mk4.014958.00 | Eukaryotic translation initiation factor 5 |
Schmidtea mediterranea | mk4.018235.01 | Eukaryotic translation initiation factor 5 |
Schmidtea mediterranea | mk4.017823.00 | Eukaryotic translation initiation factor 5 |
Schmidtea mediterranea | mk4.005027.00 | Eukaryotic translation initiation factor 5 |
Schmidtea mediterranea | mk4.007046.01 | Eukaryotic translation initiation factor 5 |
Trypanosoma brucei gambiense | Tbg972.10.3450 | eukaryotic translation initiation factor 5, putative |
Trypanosoma brucei | Tb927.10.2770 | eukaryotic translation initiation factor 5, putative |
Trypanosoma congolense | TcIL3000_10_2380 | eukaryotic translation initiation factor 5, putative |
Trypanosoma cruzi | TcCLB.504119.10 | eukaryotic translation initiation factor 5, putative |
Trypanosoma cruzi | TcCLB.504105.20 | eukaryotic translation initiation factor 5, putative |
Toxoplasma gondii | TGME49_244650 | eukaryotic initiation factor-5, putative |
Theileria parva | TP03_0718 | eukaryotic translation initiation factor 5, putative |
Trichomonas vaginalis | TVAG_226360 | eukaryotic translation initiation factor, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.10.2770 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.10.2770 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.10.2770 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.10.2770 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_C37C3.2 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_C37C3.2 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_C37C3.2 | Caenorhabditis elegans | slow growth | wormbase |
CELE_C37C3.2 | Caenorhabditis elegans | sterile | wormbase |
YPR041W | Saccharomyces cerevisiae | inviable | yeastgenome |
PBANKA_0605300 | Plasmodium berghei | Essential | plasmo |
TGME49_244650 | Toxoplasma gondii | Probably essential | sidik |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.